

Ractopamine and Monensin Type C Medicated Cattle Feed

For Use in Cattle Only

INDICATIONS

For increased rate of weight gain, improved feed efficiency and prevention and control of coccidiosis due to *Eimeria bovis* and *E. zuernii* in cattle fed in confinement for slaughter during the last 28 to 42 days on feed.

ACTIVE DRUG INGREDIENTS

Ractopamine HCl ^a	8.2 to 24.6 g/ton*
Monensin, USP ^b	10 to 40 g/ton*

GUARANTEED ANALYSIS

Crude Protein, not less than	%
Non-Protein Nitrogen (NPN) ¹ , not more than	%
Crude Fat, not less than	%
Crude Fiber, not more than	%
Calcium, not less than	%
Calcium, not more than	%
Phosphorus, not less than	%
Salt ² , not less than	%
Salt ² , not more than	%
Sodium ³ , not less than	%
Sodium ³ , not more than	%
Potassium, not less than	%
Vitamin A ^{2,4} , not less than	I.U./lb

¹When added.

²If added.

³Shall be guaranteed only when total sodium exceeds that furnished by the maximum salt guarantee.

⁴Other than precursors of Vitamin A.

INGREDIENTS

Each ingredient must be named in accordance with the names and definitions adopted by the Association of American Feed Control Officials.

FEEDING DIRECTIONS

Feed continuously as sole ration to provide 70 to 430 mg/hd/day ractopamine as ractopamine HCl, and 0.14 to 0.42 mg monensin/lb body weight per day, depending on the severity of the coccidiosis challenge, up to 480 mg/hd/day monensin for the last 28 to 42 days on feed.

CAUTION

Do not allow horses or other equines access to feeds containing monensin. Ingestion of monensin by horses has been fatal. Monensin medicated cattle feed is safe for use in cattle only. Consumption by unapproved species may result in toxic reactions. Do not exceed the levels of monensin recommended in the feeding directions, as reduced average daily gains may result. If feed refusals containing monensin are fed to other groups of cattle, the concentration of monensin in the refusals and amount of refusals fed should be taken into consideration to prevent monensin overdosing.

Ractopamine HCl is not for animals intended for breeding.

WARNING

 A withdrawal time has not been established for pre-ruminating calves. Do not use in calves to be processed for veal. 

The active ingredient in Actogain, ractopamine hydrochloride, is a beta-adrenergic agonist. Individuals with cardiovascular disease should exercise special caution to avoid exposure. Not for use in humans. Keep out of the reach of children. The Actogain 45 formulation (Type A Medicated Article) poses a low dust potential under usual conditions of handling and mixing. When mixing and handling Actogain, use protective clothing, impervious gloves, protective eyewear, and a NIOSH-approved dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse eyes thoroughly with water. If irritation persists, seek medical attention. The material safety data sheet contains more detailed occupational safety information. To report adverse effects, access medical information, or obtain additional product information, call 1-888-963-8471.

Approved by FDA under ANADA # 200-662

MANUFACTURED BY
BLUE BIRD FEED MILL
Any town, USA 12345

Net Weight lb (kg) on bag or bulk

Lot No. _____

*Final printed label on formulated Type C medicated feed must bear a single concentration of each drug.

^aSourced from Actogain[®], ANADA # 200-548

^bSourced from Monovet[®], ANADA # 200-639

Actogain is a registered trademark of Zoetis Inc.

Monovet is a registered trademark of Huvepharma EOOD.